No Result
View All Result
  • Home
  • Stock Watchlist
  • Stock Analyst News
  • Earnings News
  • Insider Trades
  • Dividend Stocks
Subscribe Now
  • Home
  • Market Sectors
    • Technology
    • Health
    • Finance
    • Consumer
    • Commercial Services
    • Electronic
    • Communications
    • Transportation
    • Utilities
    • Minerals
    • Other Sectors
    • Electric Vehicles
    • Pot Stock
    • 5G Stock
    • Crypto
  • Stock Buys
    • Strong Buys
    • Insider Buys
  • Insider Trades
  • Dividend Stocks
  • Event Calendars
    • Earnings and Dividend
    • IPO
  • Special Reports
No Result
View All Result
HOME MARKET SECTORS STOCK BUYS INSIDER TRADES DIVIDEND STOCKS
     BACK TO MENU Technology Health Finance Consumer Commercial Services Electronic Communications Transportation Utilities Minerals Other Sectors Electric Vehicles Pot Stock 5G Stock Crypto
healthtechmovers.com
No Result
View All Result

3 HealthTech Stocks Trending Now ABT stock, IOVA stock, RAIN stock

by Staff Editor
Jan 27, 2023
in Health Watchlist healthcare stocks 

We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines.  With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues.  Our watchlist includes trending 

Abbott Labs, ABT
Summary: Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.
  • Recent ABT Stock Price: $109.95
  • Yearly Gain for ABT stock: -9.82%
  • Market Cap for ABT stock: $193.54B
  • P/E Ratio for ABT stock: 28.399
Matt Miksic analyst at Barclays reiterates coverage on Abbott Labs (ABT) in the health sector with a Buy rating. TipRanks.com has Miksic rated as a 4.7 star analyst with a 65% return on investment and a 10.5% success rate. Miksic has set a price target of $ 125 for ABT stock.

Will ABT's stock price go up?  Is there an accurate ABT stock forecast available? 

TipRanks.com reports that Abbott Labs currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $123.82. The target pricing ranges from a high ABT forecast of $133.00 down to a low forecast of $107.00. Abbott Labs (ABT)’s last closing stock price was $109.95 which would put the average price target at 12.61% upside.

In addition, TradingView issued a Neutral rating for ABT stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ABT stock.

Other analysts covering ABT include:
  • Jayson Bedford of Raymond James issued a Buy rating with the price target of $ 123 on 1 day ago
  • Rick Wise of Stifel Nicolaus issued a Buy rating with the price target of $ 125 on 1 day ago
  • Anthony Petrone of Mizuho Securities issued a Hold rating with the price target of $ 110 on 1 day ago
  • Lee Hambright of Bernstein issued a Buy rating with the price target of $ 132 on 1 day ago

If you are wondering if ABT is a good stock to buy, here are 3rd party ratings for ABT stock:

  • TipRanks.com: Moderate Buy
  • TradingView.com: Neutral
  • Yahoo! Finance: Bearish Short-Term Outlook
  • Barchart.com: buy
  • Zacks.com: Hold, Top 37% (93 out of 249)

What is the sentiment on the street regarding Abbott Labs?  (Current ratings compiled by TipRanks.com)

  • News Sentiment for ABT stock: Neutral
  • Blogger Consensus for ABT stock: Bullish
  • Media Buzz for ABT stock: Very High
  • Insider Signal for ABT stock: n/a
  • Investor Sentiment for ABT stock: Very Negative
  • Hedge Fund signal for ABT stock: Negative

 The stock market is extremely volatile, and you need to do your own research on ABT stock including scouring the social networks like ABT StockTwits, Twitter and Reddit before you decide to make any investment.

Click here for ABT stock chart >>

Iovance Biotherapeutics, IOVA
Summary: Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
  • Recent IOVA Stock Price: $8.16
  • Yearly Gain for IOVA stock: -44.40%
  • Market Cap for IOVA stock: $1.22B
  • P/E Ratio for IOVA stock: -3.102
Joseph Catanzaro analyst at Piper Sandler reiterates coverage on Iovance Biotherapeutics (IOVA) in the health sector with a Buy rating. TipRanks.com has Catanzaro rated as a 4.3 star analyst with a 43% return on investment and a 10.2% success rate. Catanzaro has set a price target of $ 14 for IOVA stock.

Will IOVA's stock price go up?  Is there an accurate IOVA stock forecast available? 

TipRanks.com reports that Iovance Biotherapeutics currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $22.78. The target pricing ranges from a high IOVA forecast of $38.00 down to a low forecast of $6.00. Iovance Biotherapeutics (IOVA)’s last closing stock price was $8.16 which would put the average price target at 179.17% upside.

In addition, TradingView issued a Buy rating for IOVA stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IOVA stock.

Other analysts covering IOVA include:
  • Colleen M. Kusy of Robert W. Baird issued a Buy rating with the price target of $ 25 on 3 days ago
  • Geulah Livshits of Chardan Capital issued a Buy rating with the price target of $ 29 on 4 days ago
  • Mara Goldstein of Mizuho Securities issued a Buy rating with the price target of $ 30 on 4 days ago
  • Asthika Goonewardene of Truist Financial issued a Buy rating with the price target of $ 17 on 4 days ago

If you are wondering if IOVA is a good stock to buy, here are 3rd party ratings for IOVA stock:

  • TipRanks.com: Strong Buy
  • TradingView.com: Buy
  • Yahoo! Finance: Bullish Short-Term Outlook
  • Barchart.com: Weak sell
  • Zacks.com: Hold, Top 33% (83 out of 249)

What is the sentiment on the street regarding Iovance Biotherapeutics?  (Current ratings compiled by TipRanks.com)

  • News Sentiment for IOVA stock: Very Bullish
  • Blogger Consensus for IOVA stock: Bullish
  • Media Buzz for IOVA stock: Very High
  • Insider Signal for IOVA stock: Positive
  • Investor Sentiment for IOVA stock: Neutral
  • Hedge Fund signal for IOVA stock: Very Negative

 The stock market is extremely volatile, and you need to do your own research on IOVA stock including scouring the social networks like IOVA StockTwits, Twitter and Reddit before you decide to make any investment.

Click here for IOVA stock chart >>

Rain Therapeutics, RAIN
Summary: Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc., formerly known as Rain Therapeutics Inc., is based in NEWARK, Calif.
  • Recent RAIN Stock Price: $10.02
  • Yearly Gain for RAIN stock: 26.90%
  • Market Cap for RAIN stock: $334.19M
  • P/E Ratio for RAIN stock: -3.733
Yigal Nochomovitz analyst at Citigroup reiterates coverage on Rain Therapeutics (RAIN) in the health sector with a Buy rating. TipRanks.com has Nochomovitz rated as a 4.3 star analyst with a 46% return on investment and a 7.7% success rate. Nochomovitz has set a price target of $ 29 for RAIN stock.

Will RAIN's stock price go up?  Is there an accurate RAIN stock forecast available? 

TipRanks.com reports that Rain Therapeutics currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $18.14. The target pricing ranges from a high RAIN forecast of $29.00 down to a low forecast of $12.00. Rain Therapeutics (RAIN)’s last closing stock price was $10.02 which would put the average price target at 81.04% upside.

In addition, TradingView issued a Buy rating for RAIN stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RAIN stock.

Other analysts covering RAIN include:
  • Sam Slutsky of LifeSci Capital issued a Buy rating with the price target of $ 17 on 4 days ago
  • Graig Suvannavejh of Mizuho Securities issued a Buy rating with the price target of $ 18 on 4 days ago
  • Soumit Roy of JonesTrading issued a Buy rating with the price target of $ 20 on 4 days ago
  • Joseph Catanzaro of Piper Sandler issued a Buy rating with the price target of $ 15 on 1 week ago

If you are wondering if RAIN is a good stock to buy, here are 3rd party ratings for RAIN stock:

  • TipRanks.com: Strong Buy
  • TradingView.com: Buy
  • Yahoo! Finance: Bearish Short-Term Outlook
  • Barchart.com: Strong buy
  • Zacks.com: Buy, Top 33% (83 out of 249)

What is the sentiment on the street regarding Rain Therapeutics?  (Current ratings compiled by TipRanks.com)

  • News Sentiment for RAIN stock: Very Bullish
  • Blogger Consensus for RAIN stock: Bullish
  • Media Buzz for RAIN stock: High
  • Insider Signal for RAIN stock: Positive
  • Investor Sentiment for RAIN stock: Very Positive
  • Hedge Fund signal for RAIN stock: Neutral

 The stock market is extremely volatile, and you need to do your own research on RAIN stock including scouring the social networks like RAIN StockTwits, Twitter and Reddit before you decide to make any investment.

Click here for RAIN stock chart >>

One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.  TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

Thanks for reading!

The Editor, HealthTechMovers.com

HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.

Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================
Tags: healthcare stocks healthcare stock movers Healthcare stock watchlist health stocks RAIN 

Related Posts

From Shrinkflation to Economic Collapse: Is a Financial Storm Brewing?

Oct 13, 2024

The Week Ahead: Earnings Season Kicks Off and Retail Sales in Focus

Oct 13, 2024
Dividend 

4 Stocks Up 30%+ in 5 Days: EV, Lithium, and Tech Leaders

Oct 09, 2024
UP Fintech Holding Limited stock TIGR TIGR price target Financial Services stock watchlist Financial Services stocks 

4 Soaring Stocks Up Over 46% in 5 Days

Oct 04, 2024
Dividend 

3 Dividend Stocks Up Over 30% in the Last Week

Oct 04, 2024

Massive "Backdoor" Pre-IPO Play in Musk's $100 Billion Starlink?

Oct 03, 2024
Next Post
Canadian regulator rejects Enbridge plan to contract oil pipeline space

Canadian regulator rejects Enbridge plan to contract oil pipeline space

Nvidia’s DLSS has come to Linux gaming (but not the Steam Deck obviously)

Nvidia’s DLSS has come to Linux gaming (but not the Steam Deck obviously)

No Result
View All Result

Screener data might be 15 minutes delayed from the real time.

  • Newsletters
  • Advertise with Us
  • About Us
  • Feedback/Contact Us
  • Email Notice, Data Use and DMCA
  • Privacy Policy
  • Terms of Use and Disclaimer
  • 17B List of Disclosures
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This site contains articles and videos are offered for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation or be relied upon as personalized investment advice. We are a financial publisher. We are not financial advisors and cannot give personalized advice. There is a risk of loss in all trading, and you may lose some or all of your original investment. Results presented are not typical. Never make any investment or trade with our first consulting with your investment advisor and after doing your own due diligence. This webpage and website is protected by copyright laws of the United states and international treaties.

©2021 Sandpiper Marketing Group
PO Box 407. Mt. Mourne, NC 28123-0407

  • Home
  • Market Sectors
    • Technology
    • Health
    • Finance
    • Consumer
    • Commercial Services
    • Electronic
    • Communications
    • Transportation
    • Utilities
    • Minerals
    • Other Sectors
    • Electric Vehicles
    • Pot Stock
    • 5G Stock
    • Crypto
  • Stock Buys
    • Strong Buys
    • Insider Buys
  • Insider Trades
  • Dividend Stocks
  • Event Calendars
    • Earnings and Dividend
    • IPO
  • Special Reports

©2021 Sandpiper Marketing Group

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In